Clinical trial

Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

NCT02903524

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Doxorubicin Hydrochloride Liposome injection and cyclophosphamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention pirarubicin and cyclophosphamide Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-09-01

PhasePHASE4

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Doxorubicin Hydrochloride Liposome injection and cyclophosphamideDRUG

pirarubicin and cyclophosphamideDRUG

Sponsors & collaborators

Hebei Medical University Fourth Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02903524 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.